Marken Opens New Philadelphia Hub
News May 16, 2015
Marken has announced the opening of its newest office and warehouse in Philadelphia. The hub is the newest addition to Marken’s global drug distribution network, comprised of 10 cGMP compliant depots and more than 40 locations around the world.
The new Philadelphia facility is designed to enable the distribution of clinical trial supplies within all temperature ranges for clients with manufacturing or packaging facilities in Pennsylvania and New Jersey.
Dedicated features of this new 8865 square foot facility include a large 15 to 25ºC controlled room temperature area, a 2 to 8ºC walk in refrigerator and a -20ºC freezer. The rooms are equipped with a 24/7 temperature monitoring system, fully mapped and calibrated.
“The new Philadelphia location is an excellent addition to our worldwide network of depots and logistics facilities. It will provide easy access to our local clients and enhance our global drug distribution services by offering clients a full service staging and distribution solution in Philadelphia,” says Mark Hembarsky, Marken’s Vice President of Logistics for North America.
“The facility has been built to Marken’s exact specifications and will be operated under strict security with constant temperature controls. This new hub will operate like all Marken facilities, using Maestro for shipment bookings and tracking worldwide,” he adds.
Marken will host a grand opening event on Wednesday, May 27, 2015 in downtown Philadelphia for local clients. The dinner event will feature a key note presentation from an industry expert. Attendees will also have the opportunity to network and learn more about Marken’s clinical trial logistics solutions, flexible depot network and other value added services.
With 35 years of experience and 100% dedication to the life sciences industry, Marken will continue to expand its global presence to support the increase in size and complexity of the drug distribution market.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019